P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

• E. Kastritis,
• M. C. Minnema,
• M. A. Dimopoulos,
• G. Merlini,
• F. Theodorakakou,
• D. Fotiou,
• A. Huart,
• K. Belhadj,
• S. Gkolfinopoulos,
• K. Manousou,
• P. Sonneveld,
• G. Palladini

Affiliations

E. Kastritis

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

M. C. Minnema

2 Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands

M. A. Dimopoulos

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

G. Merlini

3 Amyloidosis Research and Treatment Center, University of Pavia, Pavia, Italy

F. Theodorakakou

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

D. Fotiou

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

A. Huart

4 Department of Nephrology and transplantation, Rangueil University Hospital, Toulouse

K. Belhadj

5 Lymphoid Malignancies Unit, Henri Mondor Hospital, Créteil, France

S. Gkolfinopoulos

6 Health Data Specialists, Dublin, Ireland

K. Manousou

6 Health Data Specialists, Dublin, Ireland

P. Sonneveld

7 Erasmus MC Cancer Institute, Rotterdam, Netherlands

G. Palladini

3 Amyloidosis Research and Treatment Center, University of Pavia, Pavia, Italy